Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of human fetal lung fibroblast line in preparation of hepatitis A vaccines

A technology of fibroblasts and human embryonic lungs, applied in the field of vaccines, can solve the problems of limiting the increase and further use of virus production, and the use of cells without promoting the use of cell generations, so as to avoid cell protein residues, good immune effect, and safety high effect

Active Publication Date: 2014-01-22
云南沃森生物技术股份有限公司
View PDF8 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But the disadvantage is that the cells are not promoted and used and the cell generation is high, which limits the improvement of virus production and further use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human fetal lung fibroblast line in preparation of hepatitis A vaccines
  • Application of human fetal lung fibroblast line in preparation of hepatitis A vaccines
  • Application of human fetal lung fibroblast line in preparation of hepatitis A vaccines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Preparation of embodiment 1 Walvax-2 cell strain

[0025] 1.1. Acquisition of experimental materials: After obtaining the approval of the national health management department and the ethics committee, investigate the age, occupation and health status of the couples who donate pregnant women, as well as the three generations of parents of the fetus. Fetuses with a family history of genetic defects. After obtaining the consent of the parents of the fetus and their relatives, sign the "Donor Consent".

[0026] 1.2. Primary culture: embryos sent to the laboratory in time after induction of water sac, the lung tissue was taken out under sterile conditions, the membrane on the surface of the lung tissue was torn off, and cut into 1-2 mm 3 The tissue pieces were washed with PBS for 3 to 4 times; the tissue pieces were transferred into the Erlenmeyer flask; digested with trypsin for 30 minutes, neutralized with serum, centrifuged at 1000rpm for 5 minutes to discard the trypsi...

Embodiment 2

[0032] Embodiment 2 prepares hepatitis A inactivated vaccine with Walvax-2 cell line

[0033] 2.1 Cell factory preparation of Walvax-2 cells

[0034] Walvax-2 cells were resuscitated in T75 flasks for 20 passages, the cell viability rate was above 99%, and cultured in a closed manner at 37°C±0.5°C until the cells covered the growth surface, digested with 0.25% trypsin, and passaged at a split ratio of 1:2 Cultivated to a cell mass that can be used for large-scale production in bioreactors. After the cells were digested, they were collected into Erlenmeyer flasks and waited to be inoculated with the virus. The cell growth medium in the cell culture medium is MEM nutrient solution containing 10% newborn bovine serum by volume.

[0035] 2.2 Walvax-2 cells inoculated with HAV virus

[0036] The collected Walvax-2 cells were sampled and counted, the cell concentration was adjusted, and the hepatitis A virus YN5 strain CCTCC NO:V200104 was inoculated. The MOI of infection was 0.5...

Embodiment 3

[0048] The immunogenicity detection of embodiment 3 different concentrations hepatitis A inactivated vaccines

[0049] The immunogenicity of inactivated hepatitis A vaccine was tested by in vivo potency in mice. ED50 is the half effective dose, which refers to the dose of the vaccine that causes half of the animal-specific antibody positive reactions in a group of animals. For the same animal in different vaccines or different contents of the same vaccine, the lower the ED50 value, the higher the ability of an animal to produce specific antibodies.

[0050] Adopt the production method of the present invention to prepare a batch of hepatitis A inactivated vaccines, the batch number is 20110403, the virus titer is 40960EU / ml, the adjusted hepatitis A antigen content is respectively 2000EU / 0.5ml, 2400EU / 0.5ml, 2800EU / 0.5ml and 3200EU / 0.5 ml. 260 ICR mice (SFP grade) aged 4-6 weeks were selected as mice. Hepatitis A inactivated vaccines of each antigen concentration (with Al(OH...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a human diploid fibroblast line Walvax-2 in the preparation of hepatitis A vaccines. The human diploid fibroblast line is susceptible to hepatitis A viruses. A human diploid cell hepatitis A virus purifying vaccine having the advantages of high antigen purity, good immunization effect, high security and low price can be obtained by adopting the Walvax-2 to produce the hepatitis A vaccines.

Description

[0001] Field of the invention: [0002] The invention belongs to the technical field of vaccines, in particular, the invention relates to the application of human diploid fibroblast cell strains in the preparation of hepatitis A vaccine, and the application of human diploid fibroblast cell strains in vaccines for treating hepatitis A disease . Background technique: [0003] Hepatitis A (hepatitis A), also known as hepatitis A, is an infectious disease mainly caused by hepatitis A virus (HAV) and liver inflammation. It is an important health problem in my country. Fecal-oral transmission is the main form, and it can be transmitted at any age, but it is mainly children and adolescents. The case fatality rate is low, and most of the severe patients are children. [0004] HAV belongs to Picornaviridae, a separate genus. Unenveloped, spherical particles with a diameter of 27nm to 32nm and icosahedral stereosymmetry. Hepatotropic, strong environmental tolerance, acid and heat res...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/00A61K39/29A61P31/14C12R1/93
CPCY02A50/30
Inventor 马波杨喆何丽芳王丽丽陈敏王馨
Owner 云南沃森生物技术股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com